| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
|
Ravaud, A.
|
|
|
20 |
5 |
p. 966-967
|
artikel
|
| 2 |
Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer
|
Hotta, K.
|
|
|
20 |
5 |
p. 829-834
|
artikel
|
| 3 |
Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial
|
Biffi, R.
|
|
|
20 |
5 |
p. 935-940
|
artikel
|
| 4 |
Brain metastases and subtypes of breast cancer
|
Pestalozzi, B.C.
|
|
|
20 |
5 |
p. 803-805
|
artikel
|
| 5 |
BRCA-deficient animal models and cisplatin resistance
|
Muggia, F.
|
|
|
20 |
5 |
p. 962
|
artikel
|
| 6 |
Can a brief psychological intervention prevent anxiety or depressive disorders in cancer patients? A randomised controlled trial
|
Pitceathly, C.
|
|
|
20 |
5 |
p. 928-934
|
artikel
|
| 7 |
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer
|
Serrate, C.
|
|
|
20 |
5 |
p. 965
|
artikel
|
| 8 |
Editorial board
|
|
|
|
20 |
5 |
p. ii-iii
|
artikel
|
| 9 |
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
|
Corkery, B.
|
|
|
20 |
5 |
p. 862-867
|
artikel
|
| 10 |
Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer
|
Saeki, T.
|
|
|
20 |
5 |
p. 868-873
|
artikel
|
| 11 |
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
|
Barrett-Lee, P.J.
|
|
|
20 |
5 |
p. 816-827
|
artikel
|
| 12 |
Extensive-stage small-cell lung cancer—moving beyond response rate?
|
Ferraldeschi, R.
|
|
|
20 |
5 |
p. 801-802
|
artikel
|
| 13 |
Familial gastrointestinal carcinoid tumours and associated cancers
|
Hiripi, E.
|
|
|
20 |
5 |
p. 950-954
|
artikel
|
| 14 |
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas
|
Fujita, K.
|
|
|
20 |
5 |
p. 946-949
|
artikel
|
| 15 |
Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
|
West, H.L.
|
|
|
20 |
5 |
p. 850-856
|
artikel
|
| 16 |
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients
|
Ludovini, V.
|
|
|
20 |
5 |
p. 842-849
|
artikel
|
| 17 |
Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality
|
Merglen, A.
|
|
|
20 |
5 |
p. 857-861
|
artikel
|
| 18 |
Hypertension as a surrogate marker for the activity of anti-VEGF agents
|
Mir, O.
|
|
|
20 |
5 |
p. 967-970
|
artikel
|
| 19 |
in this issue
|
|
|
|
20 |
5 |
p. 799
|
artikel
|
| 20 |
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer
|
Galsky, M.D.
|
|
|
20 |
5 |
p. 965-966
|
artikel
|
| 21 |
Management of hypertension in angiogenesis inhibitor-treated patients
|
Izzedine, H.
|
|
|
20 |
5 |
p. 807-815
|
artikel
|
| 22 |
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study
|
Carlomagno, C.
|
|
|
20 |
5 |
p. 906-912
|
artikel
|
| 23 |
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
|
Takeda, K.
|
|
|
20 |
5 |
p. 835-841
|
artikel
|
| 24 |
Phase II study of sunitinib in men with advanced prostate cancer
|
Dror Michaelson, M.
|
|
|
20 |
5 |
p. 913-920
|
artikel
|
| 25 |
Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer
|
Zang, D.Y.
|
|
|
20 |
5 |
p. 892-896
|
artikel
|
| 26 |
Prescription of opioids in Italy: everything, but the morphine
|
Bandieri, E.
|
|
|
20 |
5 |
p. 961-962
|
artikel
|
| 27 |
Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma
|
Kim, M.S.
|
|
|
20 |
5 |
p. 955-960
|
artikel
|
| 28 |
Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
|
Bono, P.
|
|
|
20 |
5 |
p. 967
|
artikel
|
| 29 |
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
|
Posner, M.R.
|
|
|
20 |
5 |
p. 921-927
|
artikel
|
| 30 |
Table of Contents
|
|
|
|
20 |
5 |
p. iv-v
|
artikel
|
| 31 |
The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients
|
Sun, Z.
|
|
|
20 |
5 |
p. 897-905
|
artikel
|
| 32 |
The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials
|
Chau, I.
|
|
|
20 |
5 |
p. 885-891
|
artikel
|
| 33 |
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
|
Garm Spindler, K. -L.
|
|
|
20 |
5 |
p. 879-884
|
artikel
|
| 34 |
The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer
|
Numico, G.
|
|
|
20 |
5 |
p. 941-945
|
artikel
|
| 35 |
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling
|
Pensabene, M.
|
|
|
20 |
5 |
p. 874-878
|
artikel
|
| 36 |
Value of CA 15-3 determination in the initial management of breast cancer patients
|
Chourin, S.
|
|
|
20 |
5 |
p. 962-964
|
artikel
|
Tijdschrift beschrijving